CN108936632A - 一种磷虾油软胶囊及其制备方法 - Google Patents
一种磷虾油软胶囊及其制备方法 Download PDFInfo
- Publication number
- CN108936632A CN108936632A CN201810896216.9A CN201810896216A CN108936632A CN 108936632 A CN108936632 A CN 108936632A CN 201810896216 A CN201810896216 A CN 201810896216A CN 108936632 A CN108936632 A CN 108936632A
- Authority
- CN
- China
- Prior art keywords
- parts
- bacterium powder
- krill
- capsule
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 73
- 241000239366 Euphausiacea Species 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims description 27
- 239000000843 powder Substances 0.000 claims abstract description 57
- 244000197580 Poria cocos Species 0.000 claims abstract description 19
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 19
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 18
- 229940106134 krill oil Drugs 0.000 claims abstract description 18
- 235000021323 fish oil Nutrition 0.000 claims abstract description 16
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 14
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 14
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 12
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 19
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 18
- 241001247821 Ziziphus Species 0.000 claims description 18
- 238000010992 reflux Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 235000013736 caramel Nutrition 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 239000004408 titanium dioxide Substances 0.000 claims description 8
- 241000220317 Rosa Species 0.000 claims description 7
- 238000013329 compounding Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000002224 dissection Methods 0.000 claims description 4
- 239000003651 drinking water Substances 0.000 claims description 4
- 235000020188 drinking water Nutrition 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000000748 compression moulding Methods 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 abstract description 7
- 230000003078 antioxidant effect Effects 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 3
- 239000006041 probiotic Substances 0.000 abstract description 3
- 235000018291 probiotics Nutrition 0.000 abstract description 3
- 239000000470 constituent Substances 0.000 abstract description 2
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000001079 digestive effect Effects 0.000 description 8
- 230000002526 effect on cardiovascular system Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 4
- 201000009240 nasopharyngitis Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 3
- 230000001151 other effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000003860 sleep quality Effects 0.000 description 3
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种磷虾油软胶囊,包括内容物和胶囊壳,按重量份计,所述内容物包括磷虾油100~1000份、鱼油100~1000份、嗜酸乳杆菌菌粉0.5~5份、乳双歧杆菌菌粉1~4.8份、鼠李糖乳杆菌菌粉0.5~5份、副干酪乳杆菌菌粉0.5~5份、红参片5~15份、枸杞子2.7~6.4份、大枣4~12份以及茯苓1~10份。本发明一种磷虾油软胶囊综合了中药组合物的活性成分、益生菌以及磷虾油、鱼油等抗氧化成分,具备多重保健功效,方便使用者长期服用。
Description
技术领域
本发明涉及功能性保健食品及药品技术领域,尤其涉及一种磷虾油软胶囊以及该磷虾油软胶囊的制备方法。
背景技术
人的记忆随着精神状态的改变会导致记忆力减退,另外,随着年龄增长由于大脑衰老,身体机能下降,或者由于营养不良等因素也会造成记忆力衰退。延缓衰老以及抗氧化是人们长期需要注意的问题。
心脑血管疾病是现代人的隐形杀手,其产生机理在于高脂血症、血液黏稠、动脉粥样硬化、高血压等所导致的心脏、大脑及全身组织发生缺血性或出血性疾病的通称,严重威胁人类健康。心脑血管疾病是50岁以上中老年人的常见病心脑血管疾病具有“发病率高、致残率高、复发率高、死亡率高、并发症多”,即“四高一多”的特点。心脑血管疾病已成为人类死亡率最高的头号杀手,人们无奈地承受着难言的生命之痛,如何保护心脑血管健康成为当前医疗健康领域需要迫切解决的一大难题。
目前,虽然市场上推出了很多具有抗氧化、增强免疫力,降血脂,增强记忆力,改善心脑血管的产品,但存在着效果不明显的缺点,保健功能单一,配方单一,很难具有多方面协同作用,不能同时具有抗氧化、增强免疫力,降血脂,增强记忆力,改善心脑血管问题,延缓衰老等多重功效。
发明内容
为了克服现有技术的不足,本发明的目的之一在于提供一种磷虾油软胶囊,以克服现有技术及产品中缺乏兼具抗氧化、增强免疫力、降血脂、增强记忆力、改善心脑血管以及延缓衰老等多重功效的保健品。
本发明的目的之二在于提供一种磷虾油软胶囊的制备方法,通过该制备方法制备出的磷虾油软胶囊既兼具有磷虾油、鱼油的抗氧化、延缓衰老、软化血管、降血脂等功效以及益生菌粉的提升消化功能、提升免疫力,还具有中药组分的改善睡眠质量、改善易疲劳状况等功效。
本发明的目的之一采用如下技术方案实现:
一种磷虾油软胶囊,包括内容物和胶囊壳,按重量份计,所述内容物包括磷虾油100~1000份、鱼油100~1000份、嗜酸乳杆菌菌粉0.5~5份、乳双歧杆菌菌粉1~4.8份、鼠李糖乳杆菌菌粉0.5~5份、副干酪乳杆菌菌粉0.5~5份、红参片5~15份、枸杞子2.7~6.4份、大枣4~12份以及茯苓1~10份。
进一步地,所述磷虾油为300~700份,所述鱼油为300~700份,所述嗜酸乳杆菌菌粉为1~3份,所述乳双歧杆菌菌粉为1.2~2.5份,所述鼠李糖乳杆菌菌粉为1~3份,所述副干酪乳杆菌菌粉1~3份,所述红参片为7~11份,所述枸杞子为4.2~5.6份,所述大枣为6~10份,所述茯苓为4~8份。
进一步地,所述磷虾油为500份,所述鱼油为500份,所述嗜酸乳杆菌菌粉为2份,所述乳双歧杆菌菌粉为1.6份,所述鼠李糖乳杆菌菌粉为2份,所述副干酪乳杆菌菌粉2份,所述红参片为9份,所述枸杞子为4.8份,所述大枣为8份,所述茯苓为6份。
进一步地,所述胶囊壳包括明胶100~500份、纯化水100~500份、甘油100~300份、焦糖1~10份、二氧化钛0.5~1.5份以及胭脂红0.1~0.5份。
进一步地,所述明胶为300份,所述纯化水为300份,所述甘油为150份,所述焦糖为6份,所述二氧化钛为0.9份以及所述胭脂红为0.3份。
本发明的目的之二采用如下技术方案实现:
上述任一项所述的磷虾油软胶囊的制备方法,包括以下步骤:
称取:按照配比称取磷虾油、鱼油、嗜酸乳杆菌菌粉、乳双歧杆菌菌粉、鼠李糖乳杆菌菌粉、副干酪乳杆菌菌粉、红参片、枸杞子、大枣以及茯苓,备用;
提取:将红参片、枸杞子、大枣及茯苓用50~75%的乙醇回流提取,得到的提取液经过滤得到初虑液;
复配:向初滤液中加入嗜酸乳杆菌菌粉、乳双歧杆菌菌粉、鼠李糖乳杆菌菌粉、副干酪乳杆菌菌粉,搅拌混匀并依次经低温浓缩、冷冻干燥,再向混合组分中加入磷虾油及鱼油,搅拌混匀制得内容物;
制备磷虾油软胶囊:取胶囊壳料液和内容物压制成型,制得磷虾油软胶囊。
进一步地,在称取步骤中,所述红参片、枸杞子、大枣以及茯苓切段至0.5~2cm。
进一步地,在提取步骤中,将红参片、枸杞子、大枣和茯苓置于回流提取装置内,先加入48~120重量份的饮用水,回流提取1~4h,双层绢布过滤得到第一次药渣和第一初虑液;
然后,将第一药渣倒入回流提取装置内,再加入24~60重量份的饮用水,回流提取1~4h,双层绢布过滤得到第二初虑液;
所述绢布的目数为100~200目;
合并第一初虑液和第二初虑液,制得初滤液。
进一步地,在复配步骤中,所述冷冻干燥的温度为-20℃,所述冷冻干燥的压力为-0.05MPa。
相比现有技术,本发明的有益效果在于:
(1)本发明一种磷虾油软胶囊综合了中药组合物的活性成分、益生菌以及磷虾油、鱼油等抗氧化成分,具备多重保健功效,包括改善消化功能、提升免疫力水平、降低血清总胆固醇水平、降低甘油三酯水平、抗疲劳以及改善睡眠质量等功效。该磷虾油软胶囊兼具多重保健功效,实现一种胶囊满足多重功效,方便使用者长期服用。
(2)本发明一种磷虾油软胶囊的制备方法具有制备过程简单、成本低,方便大规模生产,通过该方法制备的磷虾油软胶囊能够显著提升机体免疫力水平、改善消化功能及易疲劳状况,同时还能显著改善睡眠质量。
具体实施方式
下面,结合具体实施方式,对本发明做进一步描述,需要说明的是,在不相冲突的前提下,以下描述的各实施例之间或各技术特征之间可以任意组合形成新的实施例。
以下,通过实施例1~6来说明本发明磷虾油软胶囊的制备过程。
实施例1~6为6种不同的磷虾油软胶囊,该6种不同的磷虾油软胶囊的制备过程均包括称取步骤、提取步骤、复配步骤以及制备磷虾油软胶囊步骤。该6种不同的磷虾油软胶囊在制备过程上的差异表现为原料配比及工艺参数的不同。
称取步骤:预先将红参片、枸杞子、大枣以及茯苓切段至0.5~2cm长度。按照配比称取磷虾油、鱼油、嗜酸乳杆菌菌粉、乳双歧杆菌菌粉、鼠李糖乳杆菌菌粉、副干酪乳杆菌菌粉、红参片、枸杞子、大枣以及茯苓,备用。磷虾油、鱼油、嗜酸乳杆菌菌粉、乳双歧杆菌菌粉、鼠李糖乳杆菌菌粉、副干酪乳杆菌菌粉、红参片、枸杞子、大枣以及茯苓的用量参见表1。
表1
提取步骤:将切段的红参片、枸杞子、大枣以及茯苓添加到回流提取装置内,先加乙醇水溶液进行第一次提取。第一次提取完成后,通过双层绢布过滤,得到第一初滤液。将第一药渣倒入回流提取装置内,再加入乙醇水溶液进行第二次提取。第二次提取完成后,通过双层绢布过滤,得到第二初滤液。合并第一初滤液与第二初滤液,制得初滤液。加乙醇水溶液的量、乙醇水溶液的浓度、提取温度、提取时间以及绢布目数参见表2。
表2
实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | 实施例6 | |
第一次提取乙醇溶液用量(g) | 120 | 108 | 96 | 80 | 60 | 48 |
第一次提取乙醇溶液浓度(%) | 50 | 55 | 60 | 65 | 70 | 75 |
提取温度(℃) | 85 | 90 | 95 | 85 | 95 | 90 |
提取时间(h) | 4 | 3 | 2 | 4 | 2 | 3 |
绢布(目) | 200 | 150 | 100 | 200 | 150 | 100 |
第二次提取乙醇溶液用量(g) | 24 | 36 | 48 | 55 | 42 | 60 |
第二次提取乙醇溶液浓度(%) | 50 | 55 | 60 | 65 | 70 | 75 |
提取温度(℃) | 85 | 90 | 95 | 85 | 95 | 90 |
提取时间(h) | 4 | 3 | 2 | 4 | 2 | 3 |
绢布(目) | 200 | 150 | 100 | 200 | 150 | 100 |
复配步骤:向初滤液中加入嗜酸乳杆菌菌粉、乳双歧杆菌菌粉、鼠李糖乳杆菌菌粉、副干酪乳杆菌菌粉,搅拌混匀并依次经低温浓缩、冷冻干燥,再向混合组分中加入磷虾油及鱼油,搅拌混匀制得内容物。冷冻干燥温度以及冷冻干燥气压见表3。
表3
实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | 实施例6 | |
冷冻干燥温度(℃) | -10 | -10 | -20 | -20 | -30 | -30 |
冷冻干燥气压(MPa) | -0.03 | -0.04 | -0.05 | -0.03 | -0.04 | -0.05 |
实施例7-12为另外6种不同的磷虾油软胶囊,该6种不同的磷虾油软胶囊的制备过程均包括称取步骤、提取步骤、复配步骤和制备磷虾油软胶囊步骤。实施例7与实施例1的区别在于还包括胶囊壳组分;实施例8与实施例2的区别在于还包括胶囊壳组分;实施例9与实施例3的区别在于还包括胶囊壳组分;实施例10与实施例4的区别在于还包括胶囊壳组分;实施例11与实施例5的区别在于还包括胶囊壳组分;实施例12与实施例6的区别在于还包括胶囊壳组分。
胶囊壳组分包括明胶、纯化水、甘油、焦糖、二氧化钛以及胭脂红。制备该磷虾油软胶囊过程中,先按照表4称取明胶、纯化水、甘油、焦糖、二氧化钛以及胭脂红并混匀,制得胶囊壳组分。将胶囊壳组分用纯化水稀释、加热抽真空并过筛,制得胶囊壳料液。胶囊壳能够覆盖或者隐藏内容物的气味、味道,方便使用者口服该磷虾油软胶囊。明胶、纯化水、甘油、焦糖、二氧化钛以及胭脂红的用量参见表4。
表4
实施例7 | 实施例8 | 实施例9 | 实施例10 | 实施例11 | 实施例12 | |
明胶(g) | 100 | 200 | 300 | 350 | 400 | 500 |
纯化水(g) | 500 | 400 | 300 | 200 | 150 | 100 |
甘油(g) | 100 | 120 | 150 | 200 | 250 | 300 |
焦糖(g) | 10 | 8 | 6 | 4 | 2 | 1 |
二氧化钛(g) | 0.5 | 0.7 | 0.9 | 1 | 1.2 | 1.5 |
胭脂红(g) | 0.5 | 0.4 | 0.3 | 0.25 | 0.2 | 0.1 |
制备磷虾油软胶囊:取胶囊壳料液和内容物压制成型,制得磷虾油软胶囊。制得的磷虾油软胶囊的规格为1g/粒。
从易感冒、消化功能差的人群中选取130例充当本试验的试验者,130例试验者随机分成13组,每组10例,分别编号A、B、C、D、E、F、G、H、I、J、K、L以及对照组,其中A-L组(依次对应实施例1-12)的试验者每日早、晚各一次口服两粒实施例1-12制备的磷虾油软胶囊(1g/粒);对照组10例试验者每日照常饮食,不作任何处理。30天后停止试验并统计试验者两个月内易感冒症状和易疲劳症状的有效率,结果见表5。
有效:易感冒症状或者消化功能差症状表现为消失或者减轻。
有效率=每一组试验者中试验后易感冒症状或者消化功能差症状表现为有效的人数/该组总人数。
表5
易感冒症状(%) | 消化功能差症状(%) | |
A组 | 60 | 70 |
B组 | 70 | 70 |
C组 | 80 | 80 |
D组 | 70 | 70 |
E组 | 70 | 60 |
F组 | 60 | 60 |
G组 | 90 | 90 |
H组 | 100 | 100 |
I组 | 100 | 100 |
J组 | 100 | 100 |
K组 | 90 | 100 |
L组 | 80 | 80 |
对照组 | 0 | 10 |
表5结果表明,实施例1-12制备的磷虾油软胶囊具有良好的防止感冒、提升免疫力水平的功效,其中,实施例3及实施例8-10制备的磷虾油软胶囊表现最优。同时实施例1-12制备的磷虾油软胶囊还具有提升消化功能的功效,其中,实施例3及实施例8-10制备的磷虾油软胶囊表现最优。
动物实验
仪器及试剂:解剖器械、分光光度计,自动生化分析仪,胆固醇、胆酸钠、血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)。
测试动物:健康成年雄性大鼠(SD大鼠),体重200±20g,将成年雄性大鼠随机分成3组,分别为对照组、实验一组以及实验二组,每组8~12只。
建模:所有大鼠均给予建模饲料,建模饲料为在基础饲料的基础上添加20%蔗糖、15%猪油、1.2%胆固醇、0.2%胆酸钠,适量的酪蛋白、磷酸氢钙、石粉等。建模期为30天。
给药方法:建模结束后,对照组小鼠继续饲喂建模饲料,实验一组小鼠饲喂实施例3制备的磷虾油软胶囊一粒(1g/粒),实验二组小鼠喂实施例9制备的磷虾油软胶囊一粒(1g/粒),持续两周。
血清分析:实验结束时不禁食采血,采血后尽快分离血清,测定血清TC、TG以及LDL-C水平,测试结果见表6。
表6
TC(mmol/L) | TG(mmol/L) | LDL-C(mmol/L) | |
对照组 | 3.21±0.29 | 2.35±0.25 | 1.73±0.31 |
实验一组 | 2.12±0.23** | 1.2±0.21** | 0.59±0.22** |
实验二组 | 2.08±0.25** | 1.05±0.22** | 0.53±0.25** |
**表示为与对照组进行比较差异极显著,p<0.05。
有上述表6结果可知,实施例3和实施例9制备的磷虾油软胶囊能够显著降低小鼠血清总胆固醇(TC)水平、甘油三酯(TG)水平、低密度脂蛋白胆固醇(LDL-C)水平,总体表现为降血脂、软化血管的功效。
改善疲劳及睡眠状况的评估
随机收纳150例诊断为睡眠质量差、免疫力低下的老年患者,随机分成三组:对照组、实验一组和实验二组。统计150例老年患者在接受治疗前后的易疲劳程度、睡眠状况。治疗方法:实验一组的患者每日早晚各一次口服实施例3制备的磷虾油软胶囊两粒(1g/粒)、实验二组的患者每日早晚各一次口服实施例9制备的磷虾油软胶囊两粒(1g/粒)、对照组的患者照常饮食,持续两个月。具体易疲劳程度评估方法为:150例患者接受治疗前后均被要求连续阅读小说1h,阅读完之后征询患者的疲劳状况。疲劳程度包括:非常疲劳、疲劳感显著、略微疲劳、精力充沛四个等级。统计结果见表7。具体睡眠状况评估方法为:夜间醒来5次以上(即间歇性睡眠)或者难以入眠者计为睡眠差、夜间醒来3-4次计为睡眠较差、夜间醒来1-2次计为睡眠一般、夜间不间断睡眠计为睡眠优,共四个等级。统计结果见表8。
表7
如表7所示,治疗前后比较,实施例3制备的磷虾油软胶囊能够显著改善老年患者的易疲劳状况,实施例9制备的磷虾油软胶囊能显著改善老年患者的易疲劳状况。
表8
如表8所示,治疗前后比较,实施例3制备的磷虾油软胶囊表现出改善老年患者的睡眠状况的功效,同样,实施例9制备的磷虾油软胶囊能显著改善老年患者的睡眠状况。
上述实施方式仅为本发明的优选实施方式,不能以此来限定本发明保护的范围,本领域的技术人员在本发明的基础上所做的任何非实质性的变化及替换均属于本发明所要求保护的范围。
Claims (9)
1.一种磷虾油软胶囊,其特征在于,包括内容物和胶囊壳,按重量份计,所述内容物包括磷虾油100~1000份、鱼油100~1000份、嗜酸乳杆菌菌粉0.5~5份、乳双歧杆菌菌粉1~4.8份、鼠李糖乳杆菌菌粉0.5~5份、副干酪乳杆菌菌粉0.5~5份、红参片5~15份、枸杞子2.7~6.4份、大枣4~12份以及茯苓1~10份。
2.如权利要求1所述的磷虾油软胶囊,其特征在于,所述磷虾油为300~700份,所述鱼油为300~700份,所述嗜酸乳杆菌菌粉为1~3份,所述乳双歧杆菌菌粉为1.2~2.5份,所述鼠李糖乳杆菌菌粉为1~3份,所述副干酪乳杆菌菌粉1~3份,所述红参片为7~11份,所述枸杞子为4.2~5.6份,所述大枣为6~10份,所述茯苓为4~8份。
3.如权利要求2所述的磷虾油软胶囊,其特征在于,所述磷虾油为500份,所述鱼油为500份,所述嗜酸乳杆菌菌粉为2份,所述乳双歧杆菌菌粉为1.6份,所述鼠李糖乳杆菌菌粉为2份,所述副干酪乳杆菌菌粉2份,所述红参片为9份,所述枸杞子为4.8份,所述大枣为8份,所述茯苓为6份。
4.如权利要求1所述的磷虾油软胶囊,其特征在于,所述胶囊壳包括明胶100~500份、纯化水100~500份、甘油100~300份、焦糖1~10份、二氧化钛0.5~1.5份以及胭脂红0.1~0.5份。
5.如权利要求4所述的磷虾油软胶囊,其特征在于,所述明胶为300份,所述纯化水为300份,所述甘油为150份,所述焦糖为6份,所述二氧化钛为0.9份以及所述胭脂红为0.3份。
6.如权利要求1-5任一项所述的磷虾油软胶囊的制备方法,其特征在于,包括以下步骤:
称取:按照配比称取磷虾油、鱼油、嗜酸乳杆菌菌粉、乳双歧杆菌菌粉、鼠李糖乳杆菌菌粉、副干酪乳杆菌菌粉、红参片、枸杞子、大枣以及茯苓,备用;
提取:将红参片、枸杞子、大枣及茯苓用50~75%的乙醇回流提取,得到的提取液经过滤得到初虑液;
复配:向初滤液中加入嗜酸乳杆菌菌粉、乳双歧杆菌菌粉、鼠李糖乳杆菌菌粉、副干酪乳杆菌菌粉,搅拌混匀并依次经低温浓缩、冷冻干燥,再向混合组分中加入磷虾油及鱼油,搅拌混匀制得内容物;
制备磷虾油软胶囊:取胶囊壳料液和内容物压制成型,制得磷虾油软胶囊。
7.如权利要求6所述的磷虾油软胶囊的制备方法,其特征在于,在称取步骤中,所述红参片、枸杞子、大枣以及茯苓切段至0.5~2cm。
8.如权利要求6所述的磷虾油软胶囊的制备方法,其特征在于,在提取步骤中,将红参片、枸杞子、大枣和茯苓置于回流提取装置内,先加入48~120重量份的饮用水,回流提取1~4h,双层绢布过滤得到第一次药渣和第一初虑液;
然后,将第一药渣倒入回流提取装置内,再加入24~60重量份的饮用水,回流提取1~4h,双层绢布过滤得到第二初虑液;
所述绢布的目数为100~200目;
合并第一初虑液和第二初虑液,制得初滤液。
9.如权利要求6所述的磷虾油软胶囊的制备方法,其特征在于,在复配步骤中,所述冷冻干燥的温度为-20℃,所述冷冻干燥的压力为-0.05MPa。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810896216.9A CN108936632A (zh) | 2018-08-08 | 2018-08-08 | 一种磷虾油软胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810896216.9A CN108936632A (zh) | 2018-08-08 | 2018-08-08 | 一种磷虾油软胶囊及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108936632A true CN108936632A (zh) | 2018-12-07 |
Family
ID=64467840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810896216.9A Pending CN108936632A (zh) | 2018-08-08 | 2018-08-08 | 一种磷虾油软胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108936632A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109567207A (zh) * | 2018-12-28 | 2019-04-05 | 安徽济生元药业有限公司 | 一种能降血脂血糖鱼油磷虾油胶囊及其制备方法 |
CN113349375A (zh) * | 2021-01-07 | 2021-09-07 | 中国海洋大学 | 一种改善动脉粥样硬化脂质代谢动物双歧杆菌f1-7和磷虾油组合物制备方法及应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412227A (zh) * | 2015-12-02 | 2016-03-23 | 北京世纪合辉医药科技股份有限公司 | 一种不饱和脂肪酸膳食补充剂及其制备方法 |
CN107080258A (zh) * | 2017-04-11 | 2017-08-22 | 姜红成 | 制备具有调理人体经络补气补血功能的植物酵素的发酵组合物及制法 |
-
2018
- 2018-08-08 CN CN201810896216.9A patent/CN108936632A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412227A (zh) * | 2015-12-02 | 2016-03-23 | 北京世纪合辉医药科技股份有限公司 | 一种不饱和脂肪酸膳食补充剂及其制备方法 |
CN107080258A (zh) * | 2017-04-11 | 2017-08-22 | 姜红成 | 制备具有调理人体经络补气补血功能的植物酵素的发酵组合物及制法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109567207A (zh) * | 2018-12-28 | 2019-04-05 | 安徽济生元药业有限公司 | 一种能降血脂血糖鱼油磷虾油胶囊及其制备方法 |
CN113349375A (zh) * | 2021-01-07 | 2021-09-07 | 中国海洋大学 | 一种改善动脉粥样硬化脂质代谢动物双歧杆菌f1-7和磷虾油组合物制备方法及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015172608A1 (zh) | 一种辅助降血脂的胶囊及其制备方法 | |
CN102405951B (zh) | 一种茳茫减肥、降脂、降压、降糖饼干及其生产工艺 | |
CN107048381A (zh) | 一种改善睡眠的保健食品及其制备方法 | |
CN108936632A (zh) | 一种磷虾油软胶囊及其制备方法 | |
CN111317775A (zh) | 小儿消积止咳制剂在制备治疗发热证药物中的应用及其制备方法 | |
CN108420890B (zh) | 一种具有降血脂作用的组合物及其制备方法 | |
CN104189349B (zh) | 一种治疗月经量少的中药组合物 | |
CN114306424B (zh) | 一种治疗肥胖的中药组合物及其制备方法和应用 | |
CN101810679A (zh) | 多不饱和脂肪酸软胶囊及其制备方法 | |
CN108936631A (zh) | 一种蛋白核小球藻片及其制备方法 | |
CN101757499B (zh) | 一种治疗糖耐量低减的中药组合物 | |
CN114794478A (zh) | 一种能降低血压血脂血糖的组合物及应用 | |
CN107961293A (zh) | 一种沙棘番茄片及其制备方法 | |
WO2014134833A1 (zh) | 可食用组合物及其制备方法和包含该组合物的食品 | |
CN105995980A (zh) | 一种具有体重管理作用的组合物及其制备方法 | |
TWI664975B (zh) | 用於調控tph1基因、ddc基因及/或aanat基因表現的香蕉皮萃取物及其應用 | |
CN101623365B (zh) | 白苓健脾颗粒剂及其制备方法 | |
CN106421665B (zh) | 一种复方中药组合物在制备提高人体免疫力药物中的应用 | |
CN1248715C (zh) | 一种健胃药物及其制备方法 | |
CN109999124A (zh) | 一种黑人参鹿鞭片配方及其制备方法 | |
CN115006489B (zh) | 一种具有降血压功效的发酵黄精提取物、制备方法与应用 | |
CN114451551B (zh) | 一种温阳益气膏方及其应用 | |
CN103719866B (zh) | 一种具有减肥功效的组合物及其用途、制备方法 | |
JP3947778B2 (ja) | ハスの破砕物および/または抽出物と、乳酸菌とを含む抗アレルギー剤 | |
CN110917312B (zh) | 治疗小儿脾肺气虚型咳嗽变异性哮喘的中成药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181207 |
|
RJ01 | Rejection of invention patent application after publication |